|
Market Closed -
Nasdaq
20:57:30 14/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 213.38 USD | -0.14% |
|
+0.30% | +16.83% |
| 08-12 | UBS Adjusts Price Target on Axsome Therapeutics to $280 From $259, Keeps Buy Rating | MT |
| 08-12 | Mizuho Adjusts PT on Axsome Therapeutics to $316 From $306, Keeps Outperform Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 11.19B | - | ||||
| 80.23B | |||||
| 50.64B | |||||
| 46.87B | |||||
| 46.34B | - | ||||
| 31B |
Select your edition
All financial news and data tailored to specific country editions
